Cagrilintide vs Retatrutide: how does the research compare?
Both compounds are reviewed against the same standard: what has been studied, in whom, and what the studies reported. Human evidence and preclinical evidence are kept separate throughout.
Research education only — not medical advice
Cagrilintide
Long-acting amylin analog
- Human research
- Moderate
- Preclinical research
- Moderate
Emerging — Phase 3 trials recently reported or ongoing.
In the compound indexRetatrutide
Triple agonist (GLP-1 / GIP / glucagon)
- Human research
- Strong
- Preclinical research
- Moderate
Emerging — Phase 3 trials still in progress.
Full research profileThe Wize summary
- What each is
Cagrilintide
Long-acting amylin analog
Retatrutide
Triple agonist (GLP-1 / GIP / glucagon)
- Human evidence
Cagrilintide
moderate
Retatrutide
strong
- Preclinical evidence
Cagrilintide
moderate
Retatrutide
moderate
- What remains unknown
Cagrilintide
Emerging — Phase 3 trials recently reported or ongoing.
Retatrutide
Emerging — Phase 3 trials still in progress.
Bottom line
Human research for Cagrilintide is rated moderate, and for Retatrutide it is rated strong. That rating describes how much human research exists — not whether either compound works, and not whether either is safe.
How these two relate.
Both compounds strongly affect appetite and body weight through different receptor systems (amylin vs. triple incretin agonism). Additive appetite/weight effects are biologically plausible, but no published human combination data exists.
Detail by dimension.
Compound class
- Cagrilintide
- Long-acting amylin analog
- Retatrutide
- Triple agonist (GLP-1 / GIP / glucagon)
Mechanism being investigated
- Cagrilintide
- Amylin receptor agonist (amylin/calcitonin receptor complexes). Amylin is co-secreted with insulin and is reported to reduce appetite and slow gastric emptying.
- Retatrutide
- Activates three receptors simultaneously: GLP-1, GIP, and glucagon receptors. The glucagon component distinguishes it from dual agonists and adds reported effects on energy expenditure.
Receptor targets
- Cagrilintide
- Amylin receptors (AMY1/AMY3 calcitonin receptor complexes)
- Retatrutide
- GLP-1 receptor; GIP receptor; Glucagon receptor
Research areas
- Cagrilintide
- Metabolic research, Appetite signaling
- Retatrutide
- Metabolic research, Appetite signaling, Body composition
Half-life, as reported
- Cagrilintide
- Long-acting by design; published human half-life estimates remain limited
- Retatrutide
- ≈ 6 days (reported from Phase 2 pharmacokinetic analyses)
Human research
- Cagrilintide
- Moderate — Phase 1/2 trials as monotherapy and, importantly, in combination with semaglutide (CagriSema); Phase 3 program in progress with results reported 2024–2025.
- Retatrutide
- Strong — A Phase 2 randomized trial (24–48 weeks) reported dose-dependent weight reduction and improved cardiometabolic markers. Phase 3 is ongoing.
Preclinical research
- Cagrilintide
- Moderate — Preclinical work established the long-acting design and amylin pharmacology.
- Retatrutide
- Moderate — Preclinical studies in obese animal models reported combined effects on appetite and energy expenditure.
Mechanistic research
- Cagrilintide
- Moderate — Amylin receptor pharmacology is characterized, though less thoroughly than incretin receptors.
- Retatrutide
- Strong — Receptor pharmacology is well characterized in vitro and in animal models.
What studies reported
- Cagrilintide
- In Phase 2 and Phase 3 trials, the combination with semaglutide reported greater weight reduction than semaglutide alone.
- Retatrutide
- In a 2023 Phase 2 trial (New England Journal of Medicine), participants showed substantial dose-dependent weight reduction over 24–48 weeks, the largest reported for a peptide at that stage.
Reported adverse effects in studies
- Cagrilintide
- Reported events in trials were mostly gastrointestinal and generally mild to moderate.
- Retatrutide
- Most commonly reported trial events were gastrointestinal (nausea, vomiting, diarrhea), dose-dependent.
Research maturity
- Cagrilintide
- Emerging — Phase 3 trials recently reported or ongoing.
- Retatrutide
- Emerging — Phase 3 trials still in progress.
Study records.
Published research already verified into the Wize study library. Each record carries its own design, findings, and limitations.
Cagrilintide
No verified study record for Cagrilintide is in the Wize library yet. Records are added only once the publication has been checked against its source.
Retatrutide
No verified study record for Retatrutide is in the Wize library yet. Records are added only once the publication has been checked against its source.
Sources & research.
These are search and registry entry points, not endorsements. Every finding above should be checked against the primary publication before it is relied on.
What this comparison cannot settle.
A comparison of research is not a comparison of treatments. Where a study has directly compared Cagrilintide with Retatrutide, it appears above with a link to its record; where none appears, we have not identified one. Neither compound's evidence base can say which is more appropriate for any person, at any dose, or in any situation — and the letter on each card measures how much human research exists, not how well anything works.
Continue researching.
Continue comparing.
Get a new guide every week.
Subscribe free and the Beginner's Guide, the COA Guide, and the Safety Guide are yours the moment you sign up.